 HOUSTON, Jan. 19, 2023 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. Nasdaq: BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium ASCO GU. The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer. 